<DOC>
	<DOCNO>NCT01118494</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) result end-stage renal disease ( ESRD ) major international health problem . Many clinical marker urine protein eGFR ( evaluated glomerular filtration rate ) , estimate renal function , sensitive . As well-known , crucial role angiotensin II ( AngII ) , major effector renin-angiotensin system ( RAS ) , development renal fibrosis result ESRD widely recognized.Abundant research find intrarenal RAS take important role progression CKD . At present , clinical marker available evaluate intrarenal AngII activity difficult measure directly patient . So find establish bio-marker local renal RAS activation maybe breakthrough early detection treatment CKD . Angiotensinogen ( AGT ) know substrate renin level AGT human close Km value renin . Thus , change AGT level control activity RAS , up-regulation may lead activity Ang level . Then hypothesis AGT early bio-marker local renal RAS activation well CKD .</brief_summary>
	<brief_title>Study Urinary Angiotensinogen Marker Warn Deterioration Renal Function CKD Patients Early .</brief_title>
	<detailed_description>1 . Screening : Select CKD ( 3-4 ) patient outpatient , Urine routine examination Renal B-mode ultrasonography . 2 . Confirm : Sign consent patient meet inclusion criterion , patient include study . 3 . Create patient record complete related-inspections . 4 . Clinical follow-up : Follow-up every six month , record every patient 's disease progress every time . Each follow-up , patient need leave 5 ml blood sample 20 ml urine sample , use follow study . 5 . Detection , Observation Evaluation : Patients divide two group accord AGT level : high normal group normal group . Observe change eGFR different group . Statistics judge whether AGT early warning indicator renal function decline .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>CKD , stage 3 4 , kidney biopsy preferred selection ; Signed informed consent ; Kidney cancer patient ; Kidney transplantation ; Hereditary kidney disease ; Secondary renal disease ( diabetic nephropathy hypertensive nephropathy exclude )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>CKD</keyword>
	<keyword>RAS</keyword>
	<keyword>AGT</keyword>
</DOC>